Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Franciane Paul & Guillaume Cartron. (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Review of Clinical Immunology 15:4, pages 383-389.
Read now
Read now
Jeff P. Sharman, Andres Forero-Torres, Luciano J. Costa, Ian W. Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, Luis E. Fayad, Mark S. Kaminski, Andrew M. Evens, Christopher R. Flowers, Deniz Sahin, Kirsten E. Mundt, Thomas Sandmann, Günter Fingerle-Rowson, Charlotte Vignal, Mehrdad Mobasher & Andrew D. Zelenetz. (2019) Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & Lymphoma 60:4, pages 894-903.
Read now
Read now
Articles from other publishers (16)
Ernesto Pérez‐Persona, Laida Cuevas Palomares, Ariane Unamunzaga Cilaurren, Xabier Gutiérrez López de Ocáriz, Buenaventura Buendía Ureña, Ana Vega González de Viñaspre, Begoña Benito Ibarrondo, María Carmen Molinillo Fernández, Ana Cordero Osúa, Beatriz Benítez Delgado, Juan José García Albás, Miguel Ángel Andrés Moralejo & José María Guinea de Castro. (2023) Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima). eJHaem 4:4, pages 1196-1199.
Crossref
Crossref
Ana Muntañola, José María Arguiñano‐Pérez, Julio Dávila, Sonia González de Villambrosia, Cecilia Carpio, Ana Jiménez‐Ubieto & Antonio Salar. (2022) Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting. Clinical and Translational Science 16:2, pages 305-312.
Crossref
Crossref
Miguel A. Canales, Thomas A. Buchholz, Jaisson A.P. Bortolini, Laura M. Fogliatto, Takayuki Ishikawa, Koji Izutsu, Antonio Salar, Jeff P. Sharman, Dirk Klingbiel, Sunny Pokala, Ekaterina Vorozheikina, Peter Trask, Joana Parreira & Kai Hübel. (2023) Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis. HemaSphere 7:4, pages e860.
Crossref
Crossref
Mark Bishton, Scott Marshall, Jatinder Harchowal, Gilles Salles, Camille Golfier, Alessandra Tucci, Alicia Rodriguez Fernández, Jose Javier Sanchez Blanco, Monica Bocchia, SooKyoung Kim, Young Nam Lee & Pier Luigi Zinzani. (2022) The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe. Hematological Oncology 40:3, pages 370-380.
Crossref
Crossref
Katherine A Moser, Randall W Knoebel, Connor Roth, Sandeep Parsad & Zachary Schlei. (2022) Impact of electronic interventions on guideline concordant ordering of rituximab infusion rate. Journal of Oncology Pharmacy Practice 28:5, pages 1157-1162.
Crossref
Crossref
Daisuke Tsutsumi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Shinya Tsuboi, Susumu Otsuka, Yoshihiro Hatta & Yukinaga Kishikawa. (2021) A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. International Journal of Clinical Pharmacy 44:2, pages 366-373.
Crossref
Crossref
Donald C Moore, Tsion Gebru & Dragos Plesca. (2020) Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. Journal of Oncology Pharmacy Practice 27:8, pages 1914-1918.
Crossref
Crossref
Kelly J. Gaffney, Elizabeth M. Dahl, Michael P. StantonJrJr, Elizabeth Starek & Anthony S. Zembillas. (2020) Rapid-Infusion Rituximab in a Pediatric Population. The Journal of Pediatric Pharmacology and Therapeutics 25:3, pages 215-219.
Crossref
Crossref
Thomas Schlake, Andreas Thess, Moritz Thran & Ingo Jordan. (2018) mRNA as novel technology for passive immunotherapy. Cellular and Molecular Life Sciences 76:2, pages 301-328.
Crossref
Crossref
Ciara L. Freeman & Laurie Sehn. (2018) Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. Current Oncology Reports 20:12.
Crossref
Crossref
Ken Ohmachi, Kiyoshi Ando, Tomohiro Kinoshita, Kyoya Kumagai, Kiyohiko Hatake, Takayuki Ishikawa, Takanori Teshima, Koji Kato, Koji Izutsu, Eisuke Ueda, Kiyohiko Nakai, Hiroshi Kuriki & Kensei Tobinai. (2018) Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. Japanese Journal of Clinical Oncology 48:8, pages 736-742.
Crossref
Crossref
Samuel Luke Hill & Andrew Davies. (2018) Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Future Oncology 14:17, pages 1691-1699.
Crossref
Crossref
Lisa Modelevsky, Richard Tizon, Samantha N Reiss, Marcel Smith, Rachel Garonce & Thomas Kaley. (2018) Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. CNS Oncology 7:3, pages CNS19.
Crossref
Crossref
Andrew Davies, Claude Berge, Axel Boehnke, Anjum Dadabhoy, Pieternella Lugtenburg, Simon Rule, Mathias Rummel, Christine McIntyre, Rodney Smith & Xavier Badoux. (2017) Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy 34:10, pages 2210-2231.
Crossref
Crossref
Kensei Tobinai, Christian Klein, Naoko Oya & Günter Fingerle-Rowson. (2016) A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Advances in Therapy 34:2, pages 324-356.
Crossref
Crossref
Emily Dotson, Brooke Crawford, Gary Phillips & Jeffrey Jones. (2015) Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. Supportive Care in Cancer 24:3, pages 1125-1129.
Crossref
Crossref